Project Grant R44AI197362
Award Date 8/21/26
Completion Date 7/31/29
Dollars Obligated $999K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Research Triangle Park, Durham, NC, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Institute For Systems Biology $940,934 on June 12, 2026, for research on canonical and non-canonical phosphorylation events in bacterial pathogens under CFDA 93.855 (Allergy and Infectious Diseases Research). The project develops and applies engineered affinity reagents called phosphopeptide "superbinders" to interrogate phosphorylation in bacterial pathogens. Traditional immobilized metal affinity chromatography...
- The National Institute of Allergy and Infectious Diseases awarded the University of Rochester $162,000 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on genome organization in dendritic cell development. The project, titled "Elucidating the Role of Genome Organization in CDC1 Development," investigates how the cohesin protein complex controls the epigenetic regulation of type 1 conventional dendritic cell (CDC1)...
- The National Institute of Allergy and Infectious Diseases awarded President and Fellows of Harvard College $295,750 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to benchmark single-lineage RNA-seq (SLRNA-SEQ), an innovative technology for transcriptome analysis of microbial lineages with sensitivity exceeding current single-microbe methods. The award funds development and validation of SLRNA-SEQ using capsules with amphiphilic gel envelopes (CAGES) to...
- The National Institute of Allergy and Infectious Diseases awarded $118,332 to the University of North Carolina at Charlotte on October 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop multifunctional RNA/DNA hybrid nanoassemblies capable of simultaneously activating the cGAS-STING and RIG-I immune pathways while incorporating real-time fluorescent monitoring. The approach involves engineering non-functional RNA/DNA hybrids carrying partial agonists...
- The National Institute of Allergy and Infectious Diseases awarded Vivid Bioinnovations, PBC $299,991 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a spatially resolved single-cell DNA sequencing platform for spatial genomics with application to HIV reservoir mapping. The recipient will develop the first commercially viable spatial genomics platform integrating hydrogel-based spatial barcoding, droplet microfluidics, and Bayesian...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $191,268 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the epigenetic architecture of autoimmune risk loci, with focus on multiple sclerosis and type 1 diabetes. The award funds research into noncoding genetic variants and their role in autoimmune disease susceptibility. The project uses long-read chromatin fiber sequencing techniques...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $120,312 to the University of California, Berkeley on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into adenosine deaminases acting on RNA (ADARs), enzymes that edit RNA to regulate gene expression and immune responses. The research aims to identify viral and host...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $242,958 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate RNA structure probing approaches for understanding pro-inflammatory RNA helicases. The research applies chemical probing techniques—specifically co-transcriptional structure tracking (COSTSEQ) combined with DMS-MAPSEQ—to identify RNA substrates that DEAD-/DEAH-box helicases remodel and to map functional...
- The National Institute of Allergy and Infectious Diseases awarded $234,151 to the University of California, Davis on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the mechanism of mRNA polyadenylation in immunoglobulin heavy chain genes during the differentiation of activated B cells into plasma cells. The research leverages single-cell-level RNA measurement coupled with RNA hybridization-based flow cytometry and CRISPR-based genome...
- The National Institute of Allergy and Infectious Diseases awarded Vivid Bioinnovations, PBC $307,074 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop HIVE-SEQ, a novel omics platform for profiling single HIV-infected cells. HIVE-SEQ integrates the intact proviral DNA assay with single-cell and single-nucleus multi-omic profiling to identify and characterize cells carrying viable HIV proviruses across diverse tissues without requiring viral...